Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT825 in HER2-positive and advanced solid tumors
NCT06241456Phase 1Recruiting
- Sponsor
- Fate Therapeutics
- Start
- Jan 2024
- Primary completion
- May 2029
- Modality
- CRISPR-Cas9, CAR-T Cells, Patient-derived iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT825 in solid tumor (2 arms), sponsored by Fate Therapeutics. Primary endpoints: Dose Limiting Toxicities at 29 days, Treatment-Emergent Adverse Events at 2 years and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
FT825
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06241456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241456.